Related Experiment Videos
Improvement of tumor cell detection using a pool of monoclonal antibodies
Abstract:
It has been proven that monoclonal antibodies which are not strictly tumor specific may be useful in clinical oncology for diagnosis and in in vitro therapy. These applications, however, are hampered by the heterogeneous expression on tumor cells of the epitopes defined by the majority of monoclonal antibodies produced so far. The use of combined monoclonals could complement their antitumor specificity and solve the problem. In this perspective we selected nine monoclonal antibodies directed against different antigens of primary and metastatic breast cancer cells. The reactivity of the pool of these nine monoclonals versus a single antibody (MBr1) was determined by immunofluorescence on tumor cell lines, on frozen sections of various carcinomas, and on live cells obtained from malignant effusions. The results obtained with the pool, compared to those using MBr1 alone, showed a remarkable increase in the number of immunopositive breast and other carcinomas and the number of immunopositive cells within each positive tumor. In fact, the percentage of immunoreactive breast carcinomas increased from 79% to 100%, and the percentage of immunoreactive carcinomas of other sites from 61% to 89%. In addition, the number of positive breast carcinomas showing 100% immunoreactive cells increased from 5% with MBr1 to 71% when the pool was used.
Insights
Combining multiple monoclonal antibodies significantly improves cancer detection and targeting. This approach enhances the identification of immunopositive cells in breast and other carcinomas, overcoming limitations of single-antibody therapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) show promise in clinical oncology for diagnosis and therapy.
- Heterogeneous antigen expression on tumor cells limits the efficacy of single mAbs.
- Combined mAbs can enhance specificity and overcome limitations of individual antibodies.
Purpose of the Study:
- To evaluate the efficacy of a pool of nine monoclonal antibodies against breast cancer antigens.
- To compare the diagnostic and therapeutic potential of combined mAbs versus a single mAb (MBr1).
Main Methods:
- Selection of nine mAbs targeting different antigens on primary and metastatic breast cancer cells.
- Immunofluorescence assays on tumor cell lines, frozen carcinoma sections, and live cells from malignant effusions.
- Comparative analysis of reactivity using the mAb pool versus MBr1 alone.
Main Results:
- The mAb pool demonstrated a significant increase in immunopositive rates for breast and other carcinomas compared to MBr1.
- Percentage of immunoreactive breast carcinomas increased from 79% to 100%; other carcinomas from 61% to 89%.
- The proportion of breast carcinomas with 100% immunoreactive cells rose from 5% (MBr1) to 71% (mAb pool).
Conclusions:
- A pool of nine monoclonal antibodies offers superior sensitivity and specificity for detecting breast and other carcinomas.
- Combined mAbs significantly enhance tumor cell identification, improving diagnostic accuracy and therapeutic potential.
- This multi-antibody approach addresses antigen heterogeneity, offering a more effective strategy in oncology.